Bio-Rad Laboratories announces the launch of a range of anti-daratumumab antibodies that are specific for daratumumab (Darzalex) and inhibit the binding of the drug to its target, CD38. These highly specific and high-affinity recombinant antibodies are suitable for bioanalysis and drug monitoring of daratumumab and its biosimilars. The new range of anti-daratumumab antibodies comprises three fully human IgG1 inhibitory antibodies with varying levels of affinity. The antibodies are ideal for use as surrogate positive controls in anti-drug antibody assays and for the development of pharmacokinetic bridging ELISAs to measure free drug. Bio-Rad’s recombinant production methods are designed to result in batch-to-batch consistency for reproducible results.

• Bio-Rad Laboratories, Inc
  For more information, see the reader service card.